Renal Care
Strategic Growth Drivers
Portfolio Innovation
~$400M
2023 New Product Revenue¹
HONG
A
Baxter
FRAM
Market Development
Improving Emerging
Market adoption
Generating evidence for
Sharesource and
HDx enabled by
Theranova
Enter Adjacencies +
Expanding the Continuum
of Care through
Chronic Kidney Disease
(CKD) Management
Treatment
Today
CKD
Renal Care Treatment
Management Services Tomorrow
Innovation And Market Development Drive Above-Market Growth Of ~5% Through 2023²
¹All references to "new products" in this presentation include new product launches, line extensions and geographic expansions, unless otherwise noted. 2All references in this presentation to future financial
expectations assume commercial execution and regulatory approvals, as applicable, consistent with Baxter's plans. CAGRS for years 2018-2023 assume constant foreign exchange rates.
| 6View entire presentation